Petr Doležel
Impact in
- Pharmaceutical Science top 2%
- Advanced Drug Delivery Systems
- Drug Solubulity and Delivery Systems
- Physiology top 5%
Papers in
-
- Cell death mechanisms and regulation 5
- RNA Interference and Gene Delivery 4
- Oncology 13
- Drug Transport and Resistance Mechanisms 12
- Co-authors
- Petr Mlejnek (33 shared papers)Petr Kosztyu (7 shared papers)David Vetchý (9 shared papers)Jitka Ulrichová (3 shared papers)Jiřı́ Vrba (3 shared papers)Jaroslav Vičar (2 shared papers)Stanislav Procházka (3 shared papers)Vladimír Divoký (3 shared papers)
- Journals
- Chemico-Biological Interactions (6 papers)Toxicology in Vitro (6 papers)Pharmaceutical Development and Technology (4 papers)BioMed Research International (3 papers)Acta Pharmaceutica (2 papers)
- Partner nations
- CzechiaUnited StatesAustria
In The Last Decade
Petr Doležel
61 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 119
- Pharmaceutical Science 177
- Physiology 68
- Hematology 103
- Oncology 179
- Genetics 67
Countries citing papers authored by Petr Doležel
This map shows the geographic impact of Petr Doležel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petr Doležel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petr Doležel more than expected).
Fields of papers citing papers by Petr Doležel
This network shows the impact of papers produced by Petr Doležel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petr Doležel. The network helps show where Petr Doležel may publish in the future.
Co-authors
The 25 scholars most cited alongside Petr Doležel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 60 | |
| 2 | 2008 | 58 | |
| 3 | 2012 | 54 | |
| 4 | 2009 | 52 | |
| 5 | 2014 | 51 | |
| 6 | 2014 | 50 | |
| 7 | 2003 | 44 | |
| 8 | 2014 | 39 | |
| 9 | 2005 | 39 | |
| 10 | 2015 | 35 | |
| 11 | 2015 | 33 | |
| 12 | 2013 | 30 | |
| 13 | 2013 | 29 | |
| 14 | 2021 | 28 | |
| 15 | 2017 | 26 | |
| 16 | 2012 | 23 | |
| 17 | 2011 | 23 | |
| 18 | 2014 | 22 | |
| 19 | 2015 | 21 | |
| 20 | 1997 | 20 |
About Petr Doležel
Petr Doležel is a scholar working on Molecular Biology, Oncology, Pharmaceutical Science, Hematology and Analytical Chemistry, having authored 61 papers that have together received 1.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (12 papers), Chronic Myeloid Leukemia Treatments (7 papers), Advanced Drug Delivery Systems (7 papers), Drug Solubulity and Delivery Systems (5 papers), Analytical Chemistry and Chromatography (5 papers), Cell death mechanisms and regulation (5 papers), RNA Interference and Gene Delivery (4 papers) and Adenosine and Purinergic Signaling (4 papers). The work is most often cited by research in Pharmaceutical Science (177 citations), Physiology (68 citations), Hematology (103 citations), Oncology (179 citations) and Genetics (67 citations). Petr Doležel has collaborated with scholars based in Czechia, United States and Austria. Frequent co-authors include Petr Mlejnek, Petr Kosztyu, David Vetchý, Jitka Ulrichová, Jiřı́ Vrba, Jaroslav Vičar, Stanislav Procházka, Vladimír Divoký, Jan Muselík and Kateřina Dvořáčková. Their work appears in journals such as Chemico-Biological Interactions, Toxicology in Vitro, Pharmaceutical Development and Technology, BioMed Research International and Acta Pharmaceutica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.